NSCLC: latest news - GoINPHARMA
Saturday, 15 December 2018 - 6:28


European Commission approves AstraZeneca’s Tagrisso

AstraZeneca has announced that the European Commission has granted marketing authorization for Tagrisso (osimertinib),which will be available in 40 and 80mg doses. The product, in tablets, is to be administered once-daily for the treatment of adult patients with locally-advanced or…

Very positive results for MSD’s Keytruda in NSCLC

MSD announced at the ESMO annual congress the results from Keynote-024, a trial investigating the use of Keytruda (pembrolizumab) vs chemotherapy in patients with NSCLC (non-small cell lung cancer). Keytruda reduced the risk of disease progression or death by 50%…